Broder MS, et al. - Researchers used data from two US claims databases (MarketScan and PharMetrics) in order to provide an update on the incidence and prevalence of lung neuroendocrine tumors (NET) in this descriptive epidemiological study. From 2009 to 2014, the estimated age-adjusted lung NET incidence for males was found to be statistically significantly increased in MarketScan. During the same time period, a statistically significant increase in age-adjusted prevalence was reported for both genders in PharMetrics. Better diagnostic methods, increased awareness of NET among clinicians and pathologists, and/or an actual increase in US disease occurrence may account for the changes in incidence and prevalence. Findings call for awareness of the clinically effective and safe treatment options available for lung NET patients among healthcare providers.